EWING, N.J., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced the availability of XYOSTED™ (testosterone enanthate) injection. XYOSTED™ is the only FDA approved ...
EWING, N.J., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) (“the Company”) today announced that the Company’s social media campaign for XYOSTED®, has been honored ...
The US Food and Drug Administration (FDA) has approved testosterone enanthate (Xyosted, Antares Pharma) subcutaneous injection for testosterone replacement therapy in men diagnosed with conditions ...
Prior to starting Xyosted, the patient's baseline cardiovascular risk should be considered and blood pressure should be adequately controlled. Antares Pharma announced the launch of Xyosted ...
Xyosted carries a Boxed Warning regarding blood pressure increases that may potentially increase the risk for major adverse cardiovascular events. The Food and Drug Administration (FDA) has approved ...
Shares of Antares Pharma (ATRS +0.00%) were up 16.7% at 12:12 p.m. EDT on Tuesday after the company gained Food and Drug Administration (FDA) approval for its testosterone treatment Xyosted. The ...
EWING, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS), a pharmaceutical technology company, today announced they have entered into an exclusive distribution agreement with ...
The US Food and Drug Administration (FDA) has declined to approve a new drug application (NDA) for testosterone enanthate (Xyosted, Antares Pharma) in a proprietary autoinjector and has raised two ...
EWING, N.J., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced that, on October 11, 2017, the Company received a letter from the U.S. Food and Drug Administration ...
Xyosted (testosterone enanthate) is a prescription drug that’s used to treat testosterone deficiency. Xyosted’s cost may depend on factors such as your dosage, whether you have health insurance, and ...
In 2018 with Xyosted, Antares brought to the market a user-friendly testosterone replacement therapy for hypogonadism, with the drug administered at home by weekly injection. Less than four years ...
Antares Pharma finally has its FDA approval for testosterone replacement therapy Xyosted—and now it's revving up to take on AbbVie's market-leading AndroGel at a 20% list-price discount. With the FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results